MediGene AG · LS:A40ESG
MediGene — H1 2021 Earnings Presentation
21 slides from MediGene's earnings presentation, Aug 12, 2021
Slide 1: Building next generation TCR-T cell therapies for solid cancers
Building next generation TCR-T cell therapies for solid cancers Medigene Half-Year Report 2021 12 August 2021 1
Slide 2: Forward looking statements disclaimer
Forward looking statements disclaimer All of the information herein has been prepared by the Company solely for use in this presentation. The information contained in this presentation has not been independently verified. No representation, warranty or undertaking, express or implied, is made as to,
Slide 3: Investment highlights
Investment highlights Powerful platform to develop best-in-class T cell-based immunotherapies for solid tumors Cutting edge ability to select optimal T cell receptors Optimal TCR properties: Higher avidity & specificity Strength in screening healthy TCR repertoires: Improved safety Collection of TCR
Slide 4: Key information
Key information Company Listing Martinsried, near Munich, Germany Frankfurt Stock Exchange (MDG1) ~70 employees ~24.6 m shares outstanding ~€22.2 m cash* ~€100 m market cap** COVID-19 Situation Update Financials Personnel H1 2020 H1 2021 2021e Work from home and on-site Total revenues €3.7 m €4.3 m
Slide 5: Validation of Medigene's TCR-T platform through partnerships
Validation of Medigene’s TCR-T platform through partnerships bluebird bio Roivant / Cytovant TCR discovery projects for multiple antigen/HLA Preclinical-stage TCR specific for the target combinations NY-ESO-1; clinical indications chosen Worldwide development and commercial rights and DC vaccine pro
Slide 6: Pipeline: A platform for excellence in solid tumors
Pipeline: A platform for excellence in solid tumors Project Target Preclinical Phase I Phase II Partner Undisclosed Solid tumors MDG10XX TBD (PRAME) Undisclosed bluebird bio (MAGE-A4) Solid tumors, Cytovant multiple myeloma, (CVT-TCR-01) (NY-ESO-1) AML, MDS Hematology MDG1011 TBD (PRAME) AML DC vacc
Slide 7: MDG1011 – TCR-Ts targeting blood cancer
MDG1011 – TCR-Ts targeting blood cancer ASH poster, 7 December 2020 Target antigen PRAME - well-characterized tumor antigen, expressed in many Other hematological and solid tumor indications Phase I/II study Combined Phase I/II study for safety, feasibility and early efficacy Indications for the Pha
Slide 8: Platform to identify optimal T cell receptors
medigene Platform to identify optimal T cell receptors
Slide 9: Discovery platform identifies "best-in-class" TCRs for solid tumors
Discovery platform identifies “best-in-class” TCRs for solid tumors Discovery of optimal affinity TCRs Tumor brings excellence to the development of TCR-T cell TCR-T products for solid tumors TCR-T Automated high-throughput platform industrializes rapid isolation of non- mutated high-affinity TCRs “
Slide 10: TCR discovery platform can address diverse forms of antigen
TCR discovery platform can address diverse forms of antigen to induce T cell responses and isolate specific TCR sequences Differentiation antigens Virus-derived antigens Examples: Tyrosinase, PSCA Examples: EBV, HPV Indications: Melanoma, prostate cancer Indications: Lymphomas, specific cancers Mino
Slide 11: Targetable tumor-specific antigens in non-coding regions – cancer's 'dark matter'
Targetable immunogenic tumor-specific antigens in non-coding regions of the genome – cancer’s ‘dark matter’ In normal cells, non-exomic regions (‘dark matter’) are not transcribed. In cancer cells, some ‘dark matter’ is transcribed and can be recognized by TCRs Peptides presented by tumors but not h
Slide 12: Addressing diversity: Multiple HLAs to cover world populations
Addressing diversity: Multiple HLAs to cover world populations • TCR-T products addressing five common HLA-A allotypes give broad population coverage • Commercial opportunity maximized with simple epitope-HLA combinations per target antigen Multiple epitopes and HLA allotypes help Example: Coverage
Slide 13: Enhanced TCR-Ts to address solid tumors
medigene Enhanced TCR-Ts to address solid tumors
Slide 14: Lead PRAME-TCR was isolated from a non-tolerized T cell repertoire
Lead PRAME-TCR was isolated from a non-tolerized T cell repertoire Priming of T cells with mature DCs Selection of Lead TCR Co-stimulatory switch receptor PD1-41BB T cells (HLA-A2 negative) 53 TCR sequences identified PRAME RNA 30 TCRs analyzed TCR selection 12 TCRs with promising HLA-A2 RNA Mature
Slide 15: Expression of PD1-41BB in TCR-Ts improves repetitive killing capacity
Expression of PD1-41BB in TCR-Ts improves repetitive killing capacity TCR TCR with Orange: Cancer cells switch Grey: TCR-T cells • TCR-T cells expressing PD1-41BB – improved killing of PD-L1-positive tumor cells. • PD1-41BB overcomes the inhibitory signal of the PD-1/PD-L1 checkpoint pathway. Images
Slide 16: Co-expression of TCR-4 with PD1-41BB strongly enhances in vitro and in vivo responses
Co-expression of TCR-4 with PD1-41BB strongly enhances in vitro and in vivo responses In vitro response In vivo efficacy ns ✱✱✱✱ 1500 1500 T cell injection Tumor volume [mm3] Tumor cells: MelA375_PD-L1 1000 1000 PRAMElow PD-L1high (pg/ml) 600 T cell injection TCR-T cells: (mm3) Tumor volume IFN UT
Slide 17: Medigene is at the forefront of TCR-T development with an extensive toolbox
Medigene is at the forefront of TCR-T development with an extensive toolbox of innovative auxiliary technologies 41 Next generation PD1-41BB co-stimulatory C 1 switch to overcome inhibitory signals in the 1 tumor milieu for greater functional TCR-T persistence in solid tumor indications Tumor cell α
Slide 18: Medigene's matrix approach
Medigene’s matrix approach Many TCRs combined with our tools result in many potential drug products used in different indications 18
Slide 19: Enhanced TCR-Ts for solid tumors
Enhanced TCR-Ts for solid tumors Cutting edge ability to select optimal T cell receptors Optimal TCR properties: Higher avidity and specificity Strength in screening healthy TCR repertoires: Improved safety Collection of TCRs against different antigens and HLAs Antigen targets of choice including un
Slide 20: Thank you — Q&A
medigene Thank you — Q&A
Slide 21: Contact
Contact Dr. Anna Niedl VP Investor Relations & Corporate Communications a.niedl@medigene.com +49 89 2000 3333 01 Medigene AG T +49 89 2000 33 0 Lochhamer Str. 11 F +49 89 2000 33 2920 82152 Planegg / Martinsried investor@medigene.com Germany www.medigene.com 21 © Medigene AG